Drug Topics

JULY 17, 2023

A Q&A with Colin Banas, MD, chief medical officer at health care software company DrFirst.

469

469

PharmaVoice

JULY 17, 2023

A new toolkit developed by industry stakeholders paves the way for faster reviews.

130

130

Drug Topics

JULY 17, 2023

The approval follows a unanimous vote of support from the FDA Antimicrobial Drugs Advisory Committee.

FDA 247

FDA 247

Pharmacy Times

JULY 17, 2023

The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.

FDA 123

FDA 123

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JULY 17, 2023

Researchers hope a new study will alleviate patients and clinicians fear of prescribing stimulants for children with ADHD.

247

247

Pharmacy Times

JULY 17, 2023

Tooth loss and gum disease may play a role in the health of the brain area that controls thinking and memory.

123

123

Pharmacy Times

JULY 17, 2023

FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.

FDA 123

FDA 123

STAT

JULY 17, 2023

Doctors have long suspected that hearing loss in older adults hastens dementia, the cognitive decline associated with aging. A new study published in The Lancet on Tuesday probes the link between the two conditions further in what could be the first randomized controlled trial of its kind.  More than 55 million people have dementia worldwide; a number that continues to grow as more people live longer.

FDA 98

FDA 98

Pharmacy Times

JULY 17, 2023

Effective implementation of the Inflation Reduction Act may allow legislators to shift their focus toward controversial pharmacy benefit manager practices, according to a panel discussion during the ATOPP Summit.

123

123

STAT

JULY 17, 2023

This is part of a series about new obesity drugs that are transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years. Read more about  The Obesity Revolution. LOS ANGELES — On this pleasant spring day, patients and uniformed health care workers crisscross the UCLA medical campus like ants on a picnic table.

98

98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

JULY 17, 2023

Every pharmacist can make a difference in patients’ lives by taking the time to understand and fulfill the community’s social and cultural needs.

Immunization 123

Immunization 123

STAT

JULY 17, 2023

Florida legislators recently passed legislation to prevent advanced practice nurses in Florida with doctorates from using the honorific “doctor.” The state House and Senate bills proposed that nurses with doctorates who introduce themselves to patients as “Dr. Smith, nurse practitioner,” could face disciplinary action. Lobbyists who supported this measure referred to it as a “patient empowerment bill that allows them to understand who is treating them.

98

98

Pharmacy Times

JULY 17, 2023

With approximately 2 years of additional follow-up, lenvatinib plus pembrolizumab maintained robust effectiveness for nearly every patient.

122

122

STAT

JULY 17, 2023

Two dominant Blue Cross Blue Shield companies in California intentionally underreported premiums of certain health plans so they could avoid paying Affordable Care Act taxes, according to new federal whistleblower complaints. These claims renew concerns about whether health insurance companies have skirted the tax code and to what extent tax fraud could exist in the industry.

Health Insurance Companies 98

Health Insurance Companies Insurance 98

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

JULY 17, 2023

Mounting concerns about availability of cancer drugs raise questions about the current supply

121

121

STAT

JULY 17, 2023

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack. The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

Hospitals 98

Hospitals FDA 98

pharmaphorum

JULY 17, 2023

Haleon nabs rights to Futura’s OTC erectile dysfunction gel Phil.

98

98

STAT

JULY 17, 2023

Westlake Village BioPartners, a West Coast biotech venture capital firm founded five years ago by two Amgen veterans, has raised a new fund and brought in two veteran investors from another biotech VC as one of its founders takes a back seat. Westlake just raised $450 million for its third fund. It’s the first without the involvement of co-founder Sean Harper, who started the firm in 2018 with his Amgen colleague Beth Seidenberg.

98

98

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

JULY 17, 2023

Friday, the Federal Trade Commission (FTC) announced its withdrawal of two policy statements outlining its former position on antitrust enforcement in healthcare markets, echoing a similar decision | The two policy statements, issued in 1996 and 2011, "no longer reflect market realities in this important sector of the economy," the regulator said.

98

98

STAT

JULY 17, 2023

Big businesses poised to profit from the advance of artificial intelligence in health care are pushing back against newly proposed federal rules meant to increase oversight and fairness of AI tools used to help make decisions about patient care. The opposition, which includes Google and Amazon as well as large health care providers, insurers, and medical software vendors, is focused on an attempt to put tighter guardrails around the use of AI by the Office of the National Coordinator for Health

Insurance 98

Insurance Patient Care 98

Fierce Healthcare

JULY 17, 2023

It took less than a week for hospital chain HCA Healthcare to go from a multimillion-patient data breach to a slew of class-action lawsuits alleging negligence and seeking relief. | The for-profit giant “knew or should have known” that the private information it collects is “highly sought after by criminal parties,” plaintiffs wrote in one complaint.

Hospitals 98

Hospitals 98

STAT

JULY 17, 2023

At the turn of the century, nearly 18 million women in the United States were battling hot flashes, night sweats, and other symptoms of menopause with hormones. But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease.

98

98

Drug Store News

JULY 17, 2023

According to the latest Brick Meets Click/Mercatus Grocery Shopping Survey, e-commerce sales slowed by 1.2% in the last month.

98

98

STAT

JULY 17, 2023

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease. The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.

98

98

The Checkup by Singlecare

JULY 17, 2023

One in 3 adults in the U.S. has prediabetes , and 80% aren’t even aware of it. This means your blood glucose (sugar) levels are higher than normal but not yet at diabetes levels. Prediabetes increases your risk for more severe and life-threatening diseases, such as heart disease, stroke, and Type 2 diabetes. In fact, without intervention, many people with prediabetes will likely have diabetes within five years.

98

98

STAT

JULY 17, 2023

The health records company NextGen Healthcare will pay $31 million to resolve allegations that it paid kickbacks to win customers and concealed shortcomings of its software to gain government certification. The settlement caps a lengthy investigation that cast a harsh light on NextGen’s efforts to gain market share in the sharp-elbowed business of selling electronic health records software.

Hospitals 98

Hospitals 98

Pharmaceutical Technology

JULY 17, 2023

The move follows a positive decision made by the EMA earlier this year, broadening the use of Veklury to the high-risk patient group.

FDA 98

FDA 98

STAT

JULY 17, 2023

Global childhood immunization coverage has nearly rebounded to pre-pandemic levels, according to a new report, with 4 million more children receiving full immunization in 2022 compared to 2021. But the report, released Monday by UNICEF and the World Health Organization (WHO), also shows that recovery is lagging in low-income countries. Overall, 20.5 million children worldwide still missed at least one vaccine that’s a part of routine immunization in 2022 — an improvement over the 2

Vaccines 98

Vaccines Immunization 98

pharmaphorum

JULY 17, 2023

Alnylam showcases long-acting amyloid drug at AAIC Phil.

98

98

STAT

JULY 17, 2023

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia. The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies.

Insurance 98

Insurance 98

Fierce Healthcare

JULY 17, 2023

Alzheimer's disease drug Leqembi recently secured full approval from the Food and Drug Administration (FDA), and more expansive coverage from Medicare followed. | If projections are met, the new Alzheimer's drug meant to slow cognitive decline will cost Medicare more than $2 billion. Does Leqembi show enough promise to override its high costs and safety concerns?

FDA 98

FDA 98

STAT

JULY 17, 2023

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of phone calls, online meetings, and deadlines has predictably returned. Yes, it may be the thick of a hot summer, but the world, such as it is, keeps spinning. So time to give it a nudge in a manageable direction with a cup of stimulation.

98

98

European Pharmaceutical Review

JULY 17, 2023

Eli Lilly and Company’s TRAILBLAZER-ALZ 2 study has shown donanemab enabled nearly half of participants at earlier stage of Alzheimer’s to experience no clinical progression at one year, according to full results from the Phase III trial. The data was shared at the 2023 Alzheimer’s Association International Conference (AAIC) and published in the Journal of the American Medical Association (JAMA).

FDA 98

FDA 98